Radioligand Therapy (RLT) with 177Lutetium-PSMA is the Treatment of Choice for the Progressive Prostate Cancer

There are a number of types of cancer with low survival rates. Although most prostate cancer can be treated well, there is a subgroup of patients who are resistant to treatment and often die from metastases. Two studies have been carried out for these very suffering patients, in which radioligand therapy (RLT) proved to be successful and superior to the usual treatments. The treatment is non-invasive and specifically targets cancer cells, similar to radioiodine therapy for thyroid cancer. It is therefore indicated in such cases and for these progressions.